Accelerating a Cancer Cure

The goal of the SPARTA study is to learn if an investigational drug, called APL-101, can help patients with non-small cell lung cancer (NSCLC) or other advanced solid tumors with a genetic alteration in c-Met oncogene (such as amplification, fusion, or EXON 14 skipping mutation). Other advanced solid tumors include, but are not limited to, brain, head and neck, gastric, esophageal, biliary, pancreatic, or colorectal cancer.

Yiviva has launched a research study to investigate whether adding YIV-906 (the study drug), comprised of four naturally derived ingredients (licorice, skullcap, peony, and dates) to sorafenib (a currently available, typical treatment for liver cancer) can increase the length of time patients with hepatocellular carcinoma (HCC) live with their disease before it worsens. The evidence-based study drug is developed from an 1800-year-old Chinese formula.